ClinicalTrials.gg
RecruitingNCT07941115HEARCONNEXUpdated Nov 17, 2026

A Clinical Trial With SENS-601, Injected With SPHYNX Administration System, in the Pediatric Population Presenting With Hearing Loss Related to Pathogenic Variation(s) of GJB2 Gene

A Phase 1/2 interventional study of SENS-601 administration in GJB2 Gene Mutation, DFNB1A and Congenital Deafness, sponsored by Sensorion. Recruiting at 1 site in France. Open to participants aged 6 Months to 6 Years. Per ClinicalTrials.gov, last updated 2026-11-17.

Primary conditionDeafnessRegistry: Hearing DisordersReclassifiedWhy we changed it
Registry
Hearing Disorders — the first condition term the registry derived for this study.
ClinicalTrials.gg
Deafness
Why
  1. The study's listed conditions name Deafness, a narrower term within Hearing Disorders.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Sensorion · Phase 1/2, Interventional, and Treatment

Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
18
Allocation
Non-randomized
Ages
6 Months to 6 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 42 studies in Deafness with a site in France — 12 open to participants now, 13 under way, none of them phase 3. Deafness · France.

Planned enrollment
20th of 24
18 · median 55
Started
2027
the only one that year
Phase 1/2
2 of 42
1 open now
Primary completion
2034-12
later than 12 of 12 live
Registered
42nd of 42
by date
Lead sponsor
3 of 42
Sensorion

Among the 42 studies in Deafness with a site in France, this one is the 20th largest by planned enrollment of the 24 interventional ones that give a count, is the only one that started in 2027, is one of 2 in phase 1/2, reaches primary completion later than 12 of the 12 other live ones, and was the 42nd registered.

Deafness

160 studies on the registry are indexed under Deafness; 46 are open to participants now.

Browse Deafness studies →

Open to participants now

12 of the 42 studies in Deafness with a site in France are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 29 Deafness studies recruiting now, 11 (38%) set no upper age limit and 9 (31%) stop at 75 or younger; 18 take children under 18; 5 take healthy volunteers.

This study: 6 Months to 6 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies in Deafness with a site in France, or all of them as a file.
02

Study summary

This study intends to assess safety, tolerability, and efficacy of SENS-601, injected with SPHYNX administration system, in children between 6 months and 6 years of age, with hearing loss related to pathogenic variation(s) of GJB2 gene.

03

Conditions studied

  • GJB2 Gene Mutation
  • DFNB1A
  • Congenital Deafness
  • Hearing Disorders
  • Ear Diseases
  • Otorhinolaryngologic Diseases
  • Deafness
  • Hearing Loss, Bilateral Sensorineural

Keywords

  • GJB2 Gene Mutation
  • Deafness
  • Connexin 26
  • HEARCONNEX
  • Hearing Loss
  • DFNB1A
  • Hearing Disorder
  • Cochlear Implant
  • SENS-601
  • Congenital Hearing Loss
  • Gene Therapy
  • Hearing Impairment
04

In context

Deafness Reclassified

160 studies on the registry are indexed under Deafness; 46 are open to participants now.

This study's planned enrollment of 18 is below the median of 43 across 106 interventional studies indexed under Deafness.

Browse Deafness studies →

Lead sponsor

Sensorion is the lead sponsor of 8 studies on the registry; 2 are open to participants now.

Compared within Deafness, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Hearing Disorders. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
6 Months to 6 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males or females aged ≥6 months to ≤6 years.
  • Congenital bilateral severe sensorineural hearing loss.
  • Biallelic GJB2 variation(s).
  • Documented normal cochlea and internal auditory canals.

Exclusion criteria

Exclusion Criteria:

  • History of chronic, acute, or major disease.
  • Have been dosed in a previous gene therapy clinical study.
  • Other causes or risk of hearing loss, including developmental disorders, unilateral hearing loss, chronic conductive hearing loss, malformation syndrome, syndromic hearing loss or any other cause that would impact negatively the response of hair cell function, history of therapy known as ototoxic for an extended period, or documented other causes of congenital bilateral hearing loss linked to mutations in genes other than GJB2.
  • Prior or current cochlear implant in the ear to be treated with SENS-601.
  • to therapy and/or or immunomodulatory therapy or to the planned surgery, to anesthesia or increased anesthesiologic risk.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

06

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
18 participants (estimated)

Study arms

  • Experimental
    Dose escalation - Dose Level 1

    Intracochlear administration of Dose level 1 of SENS-601 in one ear, with the SPHYNX injection system

    Combination Product: SENS-601 administration

  • Experimental
    Dose escalation - Dose Level 2

    Intracochlear administration of Dose level 2 of SENS-601 in one ear, with the SPHYNX injection system

    Combination Product: SENS-601 administration

  • Experimental
    Dose expansion group

    Intracochlear administration of SENS-601 in both ears, with the SPHYNX injection system, at the dose recommended following the Dose escalation phase

    Combination Product: SENS-601 administration

Interventions

  • Combination productSENS-601 administration

    Administration of SENS-601 with the SPHYNX injection system

07

What researchers measure

Primary outcomes

  1. Safety and tolerability of SENS-601 and SPHYNX administration system

    The incidence and severity of Treatment-Emergent Adverse Events (TEAEs). The incidence and severity of Adverse Device Events, Serious Adverse Device Effects, and Device Deficiencies

    Time frame: 5 years

  2. Efficacy of SENS-601 assessed by ABR

    Change from baseline of hearing threshold measured by auditory brainstem response (ABR)

    Time frame: 5 years

  3. Efficacy of SENS-601 assessed by PTA

    Change from baseline of hearing threshold measured by pure-tone audiometry (PTA)

    Time frame: 5 years

Secondary outcomes

  1. SPHYNX Injection system performance

    Incidence of successful administrations, based on user questionnaires

    Time frame: Day 1

  2. SPHYNX Injection System clinical benefit

    Incidence of failed surgeries due to SPHYNX injection system, based on "SENS-601 injection form" user questionnaires

    Time frame: Day 1

  3. Usability of the administration system

    Evaluation of the degree to which users were able to effectively, efficiently, and safely use the devices in their specific environments, based on "Usability assessment" user questionnaire

    Time frame: Day 1

08

Study locations

1 of 1 sites recruiting
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jan 2027; primary completion for Dec 2034, 95 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 20, 2026
First posted
Nov 17, 2026
StartEst.
Jan 2027
Primary completionEst.
Dec 2034
CompletionEst.
Dec 2034
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT07941115
Lead sponsor
Sensorion
Responsible party
Sponsor
First posted
Nov 17, 2026
Start date
Jan 2027 (estimated)
Primary completion
Dec 2034 (estimated)
Completion
Dec 2034 (estimated)
Last update
Nov 17, 2026

Study contacts

Lionel HOVSEPIAN
Contact
contact@sensorion-pharma.com
+33(0)686 831 180

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion